A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: A Tri-State Transplant Consortium study Correspondence

  

Authors:	Hassoun, H.; Bayer, R.; Devlin, S.; Gentile, T.; Becker, M.; O’Dweyer, K.; Lesser, M.; Landau, H.; Chung, D.; Giralt, S.
Title:	A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: A Tri-State Transplant Consortium study
Keywords:	adult; clinical article; treatment response; aged; lenalidomide; drug tolerability; cancer recurrence; cancer growth; cancer patient; letter; multiple cycle treatment; multiple myeloma; phase 2 clinical trial; blood toxicity; maintenance therapy; dexamethasone; drug dose increase; asymptomatic disease; drug dose intensification; human; male; female; priority journal
Journal Title:	Leukemia and Lymphoma
Volume:	61
Issue:	2
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2020-01-01
Start Page:	488
End Page:	490
Language:	English
DOI:	10.1080/10428194.2019.1672058
PUBMED:	31957517
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078222429&doi=10.1080%2f10428194.2019.1672058&partnerID=40&md5=e9a20a44c19d501bb8ba238a139028b2
Notes:	Letter -- Export Date: 2 March 2020 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/162090